A Comparative Clinical Efficacy Trial Of Treatments For Melancholia
Funder
National Health and Medical Research Council
Funding Amount
$309,711.00
Summary
This study seeks to improve treatment of melancholic depression by comparing three treatments, i) a selective serotonin reuptake inhibitor (SSRI), ii) cognitive behaviour therapy (CBT) and, iii) a broad-spectrum antidepressant sequencing treatment approach. We hypothesize that the latter will be superior to both i) SSRI monotherapy, and ii) CBT monotherapy, over a 12-week trial period. Comparisons will be made with the US-based Sequenced Treatment Alternatives to Relieve Depression trial.
Selective Serotonin Re-uptake Inhibitors (SSRIs) And Osteoporosis: Mechanisms And Clinical Consequences
Funder
National Health and Medical Research Council
Funding Amount
$422,964.00
Summary
Selective serotonin re-uptake inhibitors (SSRIs) are commonly used to treat depression. Serotonin is not unique to the brain but is also used by other cells in the body, including bone cells. In this project the influence of SSRIs on human osteoclast and osteoblast formation and function will be investigated in a laboratory. Additionally, the impact of SSRI use on bone loss and fracture risk in a community sample of women and men will be investigated. These studies will determine if exposure to ....Selective serotonin re-uptake inhibitors (SSRIs) are commonly used to treat depression. Serotonin is not unique to the brain but is also used by other cells in the body, including bone cells. In this project the influence of SSRIs on human osteoclast and osteoblast formation and function will be investigated in a laboratory. Additionally, the impact of SSRI use on bone loss and fracture risk in a community sample of women and men will be investigated. These studies will determine if exposure to SSRIs adversely impact bone health.Read moreRead less
PHARMACOGENETICS OF ANTIDEPRESSANT RESPONSE AND REMISSION: TOWARD GENOTYPE-GUIDED PRESCRIBING IN MAJOR DEPRESSIVE DISORDER
Funder
National Health and Medical Research Council
Funding Amount
$435,524.00
Summary
A “one-size fits all” approach to antidepressant pharmacotherapy in depression is suboptimal. Current technology and scientific data support the transition to a personalised approach to antidepressant pharmacotherapy. My research will (1) develop and test genetic based algorithms for their ability to predict antidepressant response and remission and (2) evaluate the clinical validity and utility of currently available algorithms in clinical practice.
THE EFFECT OF STRESS AND ENVIRONMENTAL ENRICHMENT ON DISEASE PROGRESSION IN MESIAL TEMPORAL LOBE EPILEPSY
Funder
National Health and Medical Research Council
Funding Amount
$578,201.00
Summary
Mesial temporal lobe epilepsy, the most common form of drug-resistant epilepsy in adults, is a progressive neurodegenerative condition for which there is currently no effective disease modifying treatment. This proposal will explore whether co-morbid stress accelerates disease progression in MTLE, and whether targeting stress pathways by medical and environmental manipulations can mitigate against this.
Predictors Of Response To Antidepressants: Utility Of Behavioural, Neuroimaging And Genetics Data
Funder
National Health and Medical Research Council
Funding Amount
$310,071.00
Summary
Major depressive disorder (MDD) is projected to cause the second greatest global burden of disease by 2020, highlighting the urgent need for valid predictors of effective treatment response. Currently, there are no accurate predictors of response to antidepressants in MDD, and successful treatment relies greatly on 'trial and error'. This process is demanding on health resources, and may be a factor in the high suicide rates in depressed patients. Previous research on treatment response has been ....Major depressive disorder (MDD) is projected to cause the second greatest global burden of disease by 2020, highlighting the urgent need for valid predictors of effective treatment response. Currently, there are no accurate predictors of response to antidepressants in MDD, and successful treatment relies greatly on 'trial and error'. This process is demanding on health resources, and may be a factor in the high suicide rates in depressed patients. Previous research on treatment response has been limited by recruitment of small, heterogeneous patient samples, lack of placebo control, and a failure to examine task related activity in brain imaging studies. Perhaps one of the more troubling aspects of research that aims to predict treatment response to antidepressant medications is the use of commonly used outcome measures such as the Hamilton Rating Depression Scale (HAM-D), which were developed long before current classification systems of depression came into use. The US Federal Drug Administration has recently identified what they call a translational gap such that behavioural and biological measures are the most robust for detection of disorders such as depression, yet these measures remain to be translated into clinical tools that can be used to evaluate treatment. The aim of the current study therefore is to determine whether genetic variability is related to treatment outcome as defined by a more objective outcome measure (facial expression perception) using a randomised controlled design. The study will also determine whether brain measures (fMRI, EEG) enhance the prediction of SSRI response to both clinical and behavioural measures, over and above the genetic contribution.Read moreRead less
Is Low Dose Amitriptyline More Effective Than Placebo In The Management Of Chronic, Neuropathic Low Back Pain? A Double-blind, Randomized, Placebo-controlled Trial With An Economic Evaluation
Funder
National Health and Medical Research Council
Funding Amount
$306,889.00
Summary
Chronic low back pain is a major public health problem in Australia. Antidepressants are a common treatment for low back pain, with physicians often prescribing them at low doses for the treatment of pain. However, the use of antidepressants for low back pain is unproven. We aim to perform a clinical trial to examine whether antidepressants are more effective than placebo in reducing pain and disability in patients with chronic low back pain.
A New Target For Antidepressant Treatment: Microglia Mediated Neuroinflammation
Funder
National Health and Medical Research Council
Funding Amount
$359,601.00
Summary
Depression is the leading cause of non-fatal disease burden in Australia. Unfortunately, current antidepressants do not provide adequate levels of relief and it is accepted that we need to develop more effective treatments. We have recently shown that a drug that reduces inflammation in the brain also reduces depression-like symptoms. This project aims to extend upon these extremely promising findings, in the hope of developing a new and more effective generation of antidepressants.
MOLECULAR STRUCTURE-FUNCTION RELATIONSHIPS OF THE NORADRENALINE TRANSPORTER & DRUG ACTION
Funder
National Health and Medical Research Council
Funding Amount
$188,912.00
Summary
The transmission of impulses by nerves is dependent on the release of chemicals, termed neurotransmitters, from the nerve. The neurotransmitter causes its effects and then its action is usually terminated by membrane proteins that transport the chemical back into the nerve. These proteins are termed 'transporters'. In the brain, psychostimulants such as cocaine and also drugs that are used in the therapy of conditions such as depression block the activity of the transporters for the neurotransmi ....The transmission of impulses by nerves is dependent on the release of chemicals, termed neurotransmitters, from the nerve. The neurotransmitter causes its effects and then its action is usually terminated by membrane proteins that transport the chemical back into the nerve. These proteins are termed 'transporters'. In the brain, psychostimulants such as cocaine and also drugs that are used in the therapy of conditions such as depression block the activity of the transporters for the neurotransmitters, noradrenaline, serotonin and dopamine. Recently, the structures of the transporter proteins have been determined using molecular biology techniques. The focus of this project is to determine the parts of the noradrenaline transporter protein structure that are important in determining its functions, utilising the knowledge that we now have about its molecular structure. This will lead to exciting advances in understanding the function of the noradrenaline transporter and these advances should ultimately lead to the development of more effective antidepressant drugs and of drugs to prevent the effects of psychostimulants such as cocaine.Read moreRead less